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Patients with diabetes mellitus presenting with acute coronary syndrome have a higher risk of cardiovascular complications and
recurrent ischemic events when compared to nondiabetic counterparts. Diﬀerent mechanisms including endothelial dysfunction,
platelet hyperactivity, and abnormalities in coagulation and ﬁbrinolysis have been implicated for this increased atherothrombotic
risk. Platelets play an important role in atherogenesis and its thrombotic complications in diabetic patients with acute coronary
syndrome. Hence, potent platelet inhibition is of paramount importance in order to optimise outcomes of diabetic patients with
acute coronary syndrome. The aim of this paper is to provide an overview of the increased thrombotic burden in diabetes and
acute coronary syndrome, the underlying pathophysiology focussing on endothelial and platelet abnormalities, currently available
antiplatelet therapies, their beneﬁts and limitations in diabetic patients, and to describe potential future therapeutic strategies to
overcome these limitations.
1.Introduction
APubMed(Medline)searchwasperformedusingthefollow-
ing terms either singly or in combination: diabetes, type 2di-
abetes mellitus, cardiovascular risk, hypercoagulability, pro-
thrombotic, acute coronary syndrome, endothelial dysfunc-
tion, antiplatelet, platelet dysfunction, aspirin, clopidogrel,
and glycoprotein IIb/IIIa inhibitor. All papers relevant to
platelet and endothelial abnormalities in diabetes mellitus,
acute coronary syndrome, and current antiplatelet therapies
were considered.
Diabetes mellitus (DM) can be described as a metabolic
disorder of multiple aetiology characterised by chronic hy-
perglycaemia with disturbances of carbohydrate, fat, and
protein metabolism resulting from defects of insulin secre-
tion, insulin action, or a combination of both [1]. The world
prevalence of diabetes among adults (aged 20–79 years) was
approximately 6.4%, aﬀecting 285 million adults in 2010 and
is predicted to rise to 7.7%, aﬀecting 439 million adults
by 2030 [2]. Between 2010 and 2030, there will be a 69%
increase in numbers of adults with diabetes in developing
countries and a 20% increase in developed countries. Glo-
bally, diabetes is likely to be the ﬁfth leading cause of death
[3]. The most prevalent form of DM is type 2 diabetes mel-
litus (T2DM). Insulin resistance usually precedes the onset
of T2DM and is commonly accompanied by other related
metabolic abnormalities such as hyperglycaemia, dyslipidae-
mia, hypertension, and prothrombotic factors, all of which
contribute to the increased cardiovascular risk. This condi-
tion is called metabolic syndrome [4, 5].
2.DiabetesandCardiovascularDisease(CVD)
A large body of epidemiological and pathological data, doc-
uments that diabetes is an important independent risk factor
for CVD in both men and women [6–8]. The incidence
of CVD, including coronary artery disease (CAD), stroke2 Cardiology Research and Practice
and peripheral arterial disease, is two- to four-fold, greater
in diabetic patients than in the general population [9].
The small vessel diabetes-speciﬁc conditions of nephropathy,
retinopathy, and possibly neuropathy and cardiomyopathy
also contribute. In patients with T2DM, CVD is responsible
for about 70% of all causes of death [10]. CVD, particularly
coronary artery disease (CAD) resulting from accelerated
atherosclerosis, is the leading cause of morbidity and mor-
tality in patients with T2DM. These patients also have a
higher risk of cardiovascular complications and recurrent
atherothrombotic events after an index event than non-DM
patients. Premenopausal women with diabetes seem to lose
most of their inherent protection against developing CVD
[11]. To make matters worse, when patients with diabetes
develop clinical CVD, they have a poorer prognosis than
the CVD patients without diabetes [12–14]. Cardiovascular
mortality in patients with DM without a history of prior
MI is comparable to mortality in nondiabetic subjects with
previous MI [9]. Hence, diabetes has been classiﬁed as a
coronary “risk equivalent” [15].
Hyperglycaemia may play an important role in increased
atherothrombotic risk in DM patients. This has been sup-
ported by the Diabetes Mellitus, Insulin Glucose Infusion in
Acute Myocardial Infarction (DIGAMI) trial. In this study,
acuteintensiveglucoseloweringtherapywithinsulin-glucose
infusion led to a reduction in mortality after 3.4 years fol-
lowup in DM patients with acute myocardial infarction [16].
However, in longstanding T2DM patients, chronic excessive
glucose lowering (glycated haemoglobin <6.0%) was asso-
ciated with increased mortality in the Action of Control
Cardiovascular Risk in Diabetes (ACCORD) study [17]. This
was supported by ADVANCE trial and VADT trial [18, 19].
3. Diabetesand AcuteCoronary
Syndrome (ACS)
Diabetes not only increases the risk of myocardial infarction
(MI) but also increases the mortality associated with the
acuteevent.ThepresenceofDMisastrongindependentpre-
dictor of short-term and long-term recurrent ischaemic
events, including mortality, in patients with acute coronary
syndrome (ACS). Studies have demonstrated poorer out-
comes among patients with diabetes following ACS. For ex-
ample, the 7-year incidence of recurrent MI in a large
population-based study was 45% in diabetic patients ver-
sus 19% in nondiabetic patients. Cardiovascular mortality
during that period was 42.0% and 15.4% in DM patients
with and without history of acute MI, respectively [9]. The
prognosis for DM patients who undergo coronary revas-
cularisation procedures is worse than that for nondiabetic
subjects [20]; DM patients experience more postprocedural
complications and have decreased infarct-free survival [21].
Mortality rates for DM patients with acute MI are 1.5–2.0
times those of non-DM patients. In-hospital and 6-month
mortality rates after an acute MI are highest among DM
patients receiving insulin therapy. The negative impact of
DMontheoutcomesismaintainedacrosstheACSspectrum,
including unstable angina and non-ST elevation myocardial
infarction (NSTEMI) [22], ST elevation myocardial infarc-
tion (STEMI) treated medically [23], and ACS undergoing
percutaneouscoronaryintervention(PCI)[24].DMpatients
have more progressive, diﬀuse, and multivessel coronary dis-
ease compared to nondiabetic patients and have poorer out-
comes after both PCI (especially with bare metal stent
[BMS]) and coronary artery bypass graft surgery (CABG),
compared to nondiabetic patients [25]. The advent of drug
eluting stents (DES) has improved PCI outcomes but the
problem of atherothrombotic complications, including stent
thrombosis, persists in diabetic patients [26].
The majority of acute CV events are precipitated by vas-
cular occlusion caused by atherosclerotic plaque disruption,
platelet aggregation, platelet adhesion, and the resulting in-
travascular thrombosis. Systems that are involved in main-
taining the integrity and patency of the vasculature including
endothelial and platelet function, coagulation, and ﬁbrinol-
ysis are impaired in diabetes, thereby shifting the balance to
favour thrombus formation.
4. Endothelial Dysfunctionand Inﬂammation
inDiabetes
Endothelial dysfunction (ED) plays an important role in
the pathogenesis and clinical expression of atherosclerosis.
It has been linked to T2DM and insulin resistance states
such as obesity in experimental and clinical studies [27]. ED
refers to an impairment of the ability of the endothelium
to properly maintain vascular homeostasis. This reﬂects a
number of abnormalities that include loss of bioavailable
nitric oxide (NO), increased production of vasoconstrictors,
and disturbed regulation of inﬂammation, thrombosis, and
cell growth in the vascular wall [28, 29]. The endothelium
plays a key role in the regulation of blood ﬂow and arterial
tone by orchestrating the production of vasodilators such as
NO, prostacyclin (PGI2) and endothelium derived hyperpo-
larisingfactor(EDHF),andvasoconstrictorsincludingendo-
thelin-1 (ET-1) and angiotensin II [28]. Vasodilators oppose
the eﬀects of vasoconstrictors and act in a homeostatic
fashion to maintain normal arterial compliance and patency.
The contribution of inﬂammation to the pathogenesis
of atherosclerosis is well recognised [30]. NO, which is
produced by a family of enzymes called endothelial NO syn-
thase (eNOS), not only causes vasodilatation but also pre-
vents leukocyte adhesion and maintains the endothelium in
a quiescent, anti-inﬂammatory state [28]. In the presence of
risk factors such as DM (hyperglycaemia), endothelial cells
are activated to express adhesion molecules such as vascular
cell adhesion molecule-1 (VCAM-1) and intercellular adhe-
sion molecule-1 (ICAM-1) which are required for leukocyte
adhesion to the endothelial surface [31]. Endothelial expres-
sion of chemotactic factors such as monocyte chemo-at-
tractant protein-1 and other proinﬂammatory cytokines like
macrophage colony stimulating factor and tumour necrosis
factor-beta (TNF-β) contributes to the inﬂammation within
the vasculature and promotes atherogenesis [31, 32]. Endo-
thelial production of prothrombotic molecules [plasmino-
gen activator inhibitor-1 (PAI-1), thromboxane, tissue factorCardiology Research and Practice 3
Table 1: Endothelial dysfunction in diabetes mellitus.
Impaired vasodilatation due to decreased NO.
Increased vasoconstriction due to increased endothelin-1.
Increased expression of adhesion molecules VCAM-1 and ICAM-1.
Increased expression of chemotactic factors and proinﬂammatory
cytokines.
Increased production of prothrombotic factors (PAI-1, TF, VWF,
thromboxane).
Increased oxidative stress.
Increased PKCβ activation.
Impaired mitochondrial biogenesis, fusion, and autophagy.
(TF) and von Willibrand’s factor (vWF)] is balanced by the
production of antithrombotic molecules such as NO, hep-
arins, prostacyclin, tissue plasminogen activator and throm-
bomodulin. Risk factors including DM shift the balance
towards a prothrombotic, antiﬁbrinolytic state (Table 1). Se-
lective impairment of phosphoinositide-3 kinase (PI3 ki-
nase)/Akt kinase signalling characterises insulin resistance
contributing to ED in T2DM [33]. Nicotinamide adenine di-
nucleotide phosphate-oxidase (NADPH oxidase) generates
superoxide anion in inﬂammatory cells and is also involved
in normal cell signalling in endothelial cells [34]. In DM,
NADPH oxidase activity and superoxide production are in-
creased [35, 36]. This increased oxidative stress impairs NO
bioavailability leading to ED. NADPH oxidase promotes
the activation of the proinﬂammatory transcription factor
[nuclear factor kappa B (NFκB)] [37]. Angiotensin II upreg-
ulates NADPH oxidase expression, and this could be one
of the reasons for angiotensin converting enzyme inhibitors
(ACEIs) having favourable vascular eﬀects in DM [38–40].
DM is associated with a systemic inﬂammatory state that
maycontributetoEDandatherosclerosis[41].Increasedglu-
cose and free fatty acid concentrations has been shown to
activate the endothelium in various experimental studies
[37, 42, 43]. Patients with DM or obesity have increased cir-
culating levels of inﬂammatory markers including C-react-
ive protein (CRP), tumour necrosis factor-alpha (TNF-α),
interleukin-6 (IL-6), and ICAM-1 [44–47]. Furthermore,
increased levels of circulating inﬂammatory markers predict
cardiovascular risk in DM patients [48].
Protein kinase C beta (PKCβ) activation may also explain
the link between inﬂammation, ED, and insulin resistance in
DM [49]. PKCs are a type of serine/threonine kinase that act
attheplasmamembraneintheregulationofsignaltransduc-
tion in various cell types. The PKCβ isoform in the endothe-
lial cells is activated by diacylglycerol (DAG) under the
conditions of increased glucose and fatty acid concentrations
[50, 51]. PKCβ reduces eNOS phosphorylation/activation
by inhibiting PI3 kinase and Akt and also activates NFκB
[52–55]. In humans, acute treatment with a PKCβ inhibitor
prevented the development of ED following glucose infusion
in the forearm of healthy volunteers and improved brachial
artery ﬂow-mediated dilatation in DM patients [56, 57].
DM and insulin resistance are strongly linked to abnor-
malities of mitochondrial function [58–60]. DM impairs
mitochondrial biogenesis, fusion, and autophagy, leading to
cellswithdecreasedmitochondrialmassandapredominance
offragmentedanddysfunctionalmitochondria[60,61].This
leads to increased amounts of reactive oxygen species and
decreased amounts of ATP. Impaired mitochondrial ener-
getics leads to increased levels of DAG which activates PKCβ
and this in turn impairs NO production. Recent work has
demonstrated links between ED, impaired mitochondrial
biogenesis, and increased mitochondrial superoxide produc-
tion in arterioles isolated from patient with DM compared to
healthy controls [62].
5.PlateletsinDiabetes:
“AngryDiabetic”Platelets
ACS is precipitated by the ischaemic eﬀect of an occlusive in-
tracoronary thrombus that develops over a ruptured athero-
matous plaque as a result of platelet adhesion and aggrega-
tion [63]. Among diabetic individuals increased platelet ag-
gregation and adhesion are due to the following.
(i) Reduced platelet membrane ﬂuidity due to changes
in the lipid composition of the membrane or glyca-
tion of membrane proteins.
(ii) Increased production of thromboxane A2 (TXA2)
from arachidonic acid metabolism, which increases
platelet sensitivity [64].
(iii) Increased expression of platelet adhesion molecules
such as CD31, CD36, CD49b, CD62P, and CD63
(when assessed by ﬂow cytometry) [65].
(iv) Upregulation of platelet ADP P2Y12 receptor sig-
nalling, which suppresses cAMP levels and lowers
insulin responsiveness, thereby leading to increased
adhesion, aggregation and pro-coagulant activity.
(v) Increased expression of platelet surface receptors
such as P-selectin, Glycoprotein (GP) Ib, and GP
IIb/IIIa [66]. GP Ib mediates platelet binding to vWF,
an important step in platelet dependent thrombosis,
andGPIIb/IIIabindstoﬁbrinogenresultinginplate-
let cross-linking as a part of the aggregation process
[67].
(vi) Increasedgenerationofplateletdependentthrombin.
(vii) Platelets are less sensitive to the eﬀects of PGI2 and
NO [68].
(viii) Platelets in T2DM show disordered calcium and
magnesium haemostasis. Intraplatelet calcium regu-
lates a variety of activities including platelet shape
change, secretion, aggregation, and TXA2 formation
[41, 69]. Increased intracellular calcium and de-
creased intracellular magnesium has been linked to
platelet hyperaggregability and adhesiveness [70].
(ix) Active platelets in DM patients are also rich in
cytokines and chemokines such as platelet factor-4,
interleukin-1β and CD40L and hence contribute to
inﬂammation and atherogenesis alongside a proco-
agulant milieu [30, 71–73].4 Cardiology Research and Practice
(x) Accelerated platelet turnover resulting in increased
reticulatedplateletsalsocontributestoplatelethyper-
activity [74].
These characteristics may play a role not only in the
higher risk of developing ACS with poorer outcomes ob-
served in DM, but also in the large proportion of DM pa-
tients with inadequate response to antiplatelet agents com-
pared to non-DM patients. This in itself may contribute to
the poorer outcomes observed in DM patients despite com-
pliance with the recommended secondary prevention ther-
apy with antiplatelet agents.
6.MicroparticlesinDiabetes
Besides platelets, microparticles (MPs) are also involved in
diabetic atherothrombosis. MPs are membrane-coated ves-
icles that emerge by budding from their parental cells upon
activation or apoptosis [75]. They retain at least some func-
tions of their cells of origin, which can include platelets,
endothelialcells,andvariousleukocytes.MPshavetheability
to activate the coagulation cascade with consequent throm-
bosis formation [76]. Platelet-derived MPs (PMPs) expose
negatively charged phospholipids which act as binding sites
for activated coagulation factors [77]. Platelet MPs also bind
tothesubendothelialmatrixandactasasubstrateforfurther
platelet adhesion via GP IIb/IIIa ﬁbrinogen bridging [78].
Resting platelets express pre-mRNA for TF, and this gets
c o n v e r t e dt om a t u r em R N Au p o np l a t e l e ta c t i v a t i o n[ 79].
This may allow platelets to synthesize active TF for throm-
bus propagation and stabilization. Monocyte-derived MPs
(MMPs) exposing TF have P-selectin glycoprotein ligand-1
which interacts with P-selectin on the surface of activated
platelets and help in further stabilization of thrombus [78].
Other possible pathways regulated by MPs include produc-
tion of lysophosphatidic acid (a strong platelet agonist),
endothelial and leukocyte activation, recruitment of mono-
cyte within the plaque, stimulation of neoangiogenesis,
induction of apoptosis in endothelial or smooth muscle cells,
and increase in TXA2 release which in turn causes vasocon-
striction [80, 81]. Increased levels of platelet-derived MPs
and their role in macrovascular complications have been
reported in DM patients [82]. Elevated levels of TF-positive
MPs have been found to correlate with components of
metabolic syndrome in patients with uncomplicated T2DM
[83, 84]. Levels of PMPs and MMPs have been shown to
correlate with DM complications like diabetic retinopathy,
which is associated with microvascular damage [85]. Ele-
vated endothelial cell-derived MPs (EMPs) are predictive
for the presence of coronary artery lesions, and are a more
signiﬁcant independent risk factor than the duration of DM,
lipidlevels,andhistoryofhypertension[86].Inpatientswith
T2DM and ACS, elevated EMPs have been linked to non-
calciﬁed atheromatous lesions as detected by multidetector
computedtomography[87].Increasedlevelsofprocoagulant
TF-positive MPs were demonstrated within the occluded
coronary artery of patients with STEMI [88]. Insulin has
been found to reduce the expression of TF in monocytes
and MMPs [89]. Beneﬁcial eﬀects of statins in T2DM and
atherothrombosis are possibly due to its eﬀects on MPs
[90–93]. All this evidence indicates that MPs are not only
a reliable marker for vascular injury but they also actively
participate in promoting atherothrombotic complications in
T2DM[76].Inthiscontext,drugsthatmayreducetherelease
of MPs and/or their thrombogenicity may have the potential
to improve the eﬀects of current antiplatelet therapy, result-
ing in lower adverse event rates in DM patients.
7.PlateletLeukocyteAggregates(PLAs)
inDiabetes
Platelets and leukocytes from DM patients are hyperreactive
and express more adhesion molecules. P-selectin is one of
the markers of platelet activation and is the main link for
platelet adhesion to circulating leukocytes [94]. Platelet P-
selectin interacts with leukocyte P-selectin glycoprotein lig-
and(PSGL-1)leadingtotheformationofPLA[95,96].Con-
sequently, activated leukocytes secrete several pro-inﬂamma-
tory cytokines and express a prothrombotic membrane phe-
notype. Elevated levels of circulating PLA have been report-
ed in various prothrombotic states including DM thereby
suggesting their involvement in the pathogenesis of athe-
rothrombosis. Elevated circulating PLA levels were found
to be linked with vascular injury in DM patients [94]. A
signiﬁcantincreaseincirculatingplatelet-polymophonuclear
aggregates (PPA) and platelet-monocyte aggregates (PMAs)
percentages was demonstrated in DM patients [97]. Inter–
estingly, percentages of circulating PPA, and PMA were
signiﬁcantly higher in DM with vascular injury compared
to DM without vascular injury suggesting the involvement
of inﬂammatory leukocytes in vascular damage [97, 98].
Increased circulating PMA percentage was found to be more
speciﬁcally a marker of diabetic microretinopathy [97].
This reinforces the fact that pro-inﬂammatory cells are
involved in microvascular complications in DM and athe-
rothrombotic process. Circulating PLA determination using
ﬂow cytometry may be used as a simple marker of micro-
vascular injury in DM patients.
8. CoagulationinDiabetes
Tissue Factor and Factor VII (F VII) initiate the thrombotic
process, resulting in the generation of thrombin. This
subsequently helps in the conversion of ﬁbrinogen into a
three-dimensional network of ﬁbrin ﬁbres which forms the
skeleton of the blood clot [99]. TF is an integral prothrom-
botic transmembrane protein expressed by both vascular
and nonvascular cells, including monocytes, macrophages,
and platelets [100]. In T2DM, TF expression is upregulated
due to the presence of low-grade inﬂammation [100]. Levels
of TF in atherosclerotic plaques in patients with unstable
angina are higher compared with those who have stable
angina [101]. Plasma TF levels are raised in subjects with
CAD particularly ACS further emphasising the role of TF
in atherothrombosis [102, 103]. Patients with T2DM have
higher circulating TF levels which are directly modulated by
glucose and insulin, and the two appear to have an additiveCardiology Research and Practice 5
Table 2: Coagulation and Fibrinolysis Dysregulation in Diabetes
Mellitus.
Impaired TF production.
Elevated F VII:c levels.
Increased thrombin generation.
High levels of IL-6 and ﬁbrinogen.
Impaired ﬁbrinolysis as a result of elevated PAI-1 levels.
eﬀect [104]( Table 2). In T2DM, increased levels of advanced
g l y c a t i o ne n dp r o d u c t sa n dr e a c t i v eo x y g e ns p e c i e sa c t i v a t e
NFκB which in turn leads to increased TF production [100].
F VII is a vitamin K dependent coagulation factor syn-
thesised in the liver. F VII coagulant activity (F VII: c) has
been associated with fatal cardiovascular events [105–107].
T2DM subjects have elevated F VII:c levels [108]. An associ-
ation between triglyceride levels and F VII:c levels has been
demonstrated; this appears to be independent of obesity and
insulin resistance [109].
Thrombin concentration inﬂuences ﬁbrin clot formation
and also determines the clot structure and stability [110].
High thrombin concentration results in denser and less per-
meableclotswhicharemoreresistanttolysis.Thrombingen-
eration is enhanced in DM secondary to low-grade coagula-
tion system activation [104, 111].
PlasmaﬁbrinogenisawellknownindependentCVDrisk
f a c t o ra n di su s e da sas u r r o g a t em a r k e rf o rC V Dr i s k[ 112].
High ﬁbrinogen levels predict silent myocardial ischaemia in
T2DM patients [113]. High levels of IL-6 in diabetes stimu-
late ﬁbrinogen synthesis by the hepatocytes, representing a
link between inﬂammation and the prothrombotic state
[114]. Insulin resistance is also associated with increased he-
patocyte ﬁbrinogen synthesis [115, 116].
9.FibrinolysisinDiabetes
Fibrinolysis is initiated by the conversion of plasminogen to
plasmin, and this is largely mediated by tissue plasminogen
activator (tPA). Plasminogen activator inhibitor-1 (PAI-1)
is the main inhibitor of ﬁbrinolysis by binding to tPA and
forming PAI-1/tPA complex. In a long-term 18-year study,
glycated haemoglobin (HbA1C) correlated positively with
PAI-1 and negatively with tPA. This implicates hypergly-
caemia as a reason for elevated PAI-1 levels [117]. Hyper-
insulinaemia also has been shown to increase PAI-1 levels,
which may account for elevated PAI-1 levels in insulin-re-
sistant states [118, 119]( Table 2).
A study indicated that clots derived from plasma puriﬁed
ﬁbrinogen in 150 diabetic subjects had a more compact
structure characterised by smaller pore size, increased ﬁbrin
thickness, and number of branch points than that from 50
healthy controls [120]. Clot lysis from diabetic patients was
slower when compared to controls due to elevated PAI-1
levels.
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Figure 1: Graph representing area of thrombus along y axis
(μ2/mm) Group 1: T2DM with CAD; Group 2: T2DM without
clinical macrovascular disease; Group 3: CAD without DM; Group
4: Healthy Controls. Adapted from [122].
10. Platelet Dependent Thrombus Formation
Arterialinjurymodelswhichsimulateinvivocoronaryartery
rheology have been used in various experimental studies
to measure platelet-dependent thrombus formation. These
provide a measure of actual thrombus which is the end
pointofallhaemostaticfunctions.Workfromourlaboratory
using the arterial injury model demonstrated increased
blood thrombogenicity and platelet dependent thrombus
formation in patients with T2DM and CAD, compared to
patients with T2DM without CAD and nondiabetic controls,
despite being on aspirin and other evidence based risk factor
therapy (Figure 1)[ 121, 122]. An improvement in blood
thrombogenicity in diabetic subjects with improved glycae-
miccontrolhasbeenshown[123].Inanotherstudy,wecom-
pared blood thrombogenicity and clot kinetics in 30 T2DM
and30nondiabeticpatients,oneweekaftertroponinpositive
non-ST elevation ACS (NSTE-ACS). In patients with T2DM,
the thrombus was increased in quantity [area of thrombus:
mean (SD) [16824.0(3619.1) versus 14413.9(4648.5)μ2/mm,
P = 0.029], weaker in tensile strength [clot index: median
(range) 0.4 (−3.3 to 4.2) versus 1.6 (−1.5to 5.4), P =
0.026] and more importantly resistant to clot retraction
[clot lysis: median (range) 27.7 (3.8–83.4) versus 73.7 (55–
191)mm/min, P = 0.017. This was despite the participants
being prescribed currently recommended secondary preven-
tion therapy including aspirin and clopidogrel, aftera NSTE-
ACS [124]. These ﬁndings may partly explain the reason for
reduced beneﬁts of current antiplatelet therapy in patients
with diabetes [125].
11.AntiplateletTherapiesinDiabetes
A clear beneﬁt of antiplatelet agents in the prevention
of atherothrombotic events in those at high risk is well
established. Multiple genetic, iatrogenic, and environmental
factors inﬂuence platelet responsiveness to these agents.
Three diﬀerent classes of antiplatelet agents are approved
for treatment and/or prevention of ACS: cyclooxygenase-1
(COX-1) inhibitors (aspirin), ADP P2Y12 receptor antago-
nists (thienopyridines), and platelet GP IIb/IIIa inhibitors
[126, 127]( Figure 2).6 Cardiology Research and Practice
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Figure 2: Schematic representation of mechanisms of action of antiplatelet agents. PAR-l: protease activated thrombin receptor-1. Adapted
from [128].
12.Aspirin
Aspirin selectively acetylates the COX-1 enzyme, thereby
blockingTXA2 synthesisinplatelets.Thiseﬀectisirreversible
since the platelets are enucleate and, therefore, unable to
resynthesise COX-1. Aspirin use for primary prevention in
DM patients has been controversial [129–131], but ongo-
ing studies including A Study of Cardiovascular Events in
Diabetes (ASCEND; NCT00135226) and Aspirin and sim-
vastatin Combination for Cardiovascular Events Prevention
Trial in Diabetes (ACCEPT-D; ISRCTN48110081) will pro-
vide further insight into this area. Aspirin, however, remains
the antiplatelet agent of choice for secondary prevention of
recurrent ischaemic events in patients with atherothrom-
botic disease including those with DM [126, 127, 132–134].
Beneﬁts of aspirin in the early management of ACS patients
including unstable angina/NSTEMI [135–137]a n dS T E M I
[138, 139] have been demonstrated consistently in various
studies. Aspirin should be given as early as possible at an
initial dose of 162 to 325mg followed by a daily maintenance
dose of 75 to 162mg [126, 127]. The recommended dose
of aspirin for secondary prevention in DM patients with
atherothrombotic disease is 75 to 162mg [133]. Withdrawal
of aspirin can lead to recurrence of ACS [140]. Two large
meta-analysis trials performed by the Antiplatelet Trialists’
Collaboration included 287 studies and involved 212000
high-risk patients (with acute or previous vascular disease or
other predisposing condition increasing the risk of occlusive
vascular disease) [141, 142]. Aspirin was the frequently used
antiplatelet agent at doses ranging from 75 to 325mg daily in
these trials. The incidence of vascular events on aspirin was
reduced from 22.3% to 18.5% in DM cohort (P<0.002)
and from 16.4% to 12.8% (P<0.00001) in non-DM cohort.
The incidence of vascular events was much higher in DM pa-
tients but the beneﬁt of antiplatelet therapy was consistent
regardless of the DM status [141]. Low-dose aspirin (75 to
150mg) was as eﬀective as higher daily doses but with signif-
icantly lower bleeding complications [141, 142]. The Clopi-
dogrel Optimal Loading Dose Usage to Reduce Recurrent
Events/Organisation to Assess Strategies in Ischaemic Syn-
dromes (CURRENT/OASIS-7) trial is the ﬁrst large-scale
randomised study comparing high- and low-dose aspirin.
This study randomised ACS patients who were scheduled
to undergo angiography within 72 hours of hospital arrival
[143, 144]. With a 2 × 2 factorial design, patients were
randomised (double blinded) to high or standard dose
clopidogrel for a month and in open label fashion to high-
dose (300 to 325mg daily) or low-dose (75 to 100mg daily)
aspirin. There was no signiﬁcant diﬀerence in the rates of the
primaryoutcome(cardiovasculardeath,MIorstrokeafter30
days) between high and low dose aspirin (4.1% versus 4.2%;
hazard ratio [HR] = 0.98; P = 0.76) in DM and non-DMCardiology Research and Practice 7
patients. A trend towards higher gastrointestinal bleeding
rates(0.38%versus0.24%;P = 0.051)inthehighdosegroup
was observed [143].
13. P2Y12 Receptor Antagonists
Platelet ADP signalling pathways mediated by P2Y1 and
P2Y12 play an important role in platelet activation and
aggregation. P2Y12 activation leads to sustained platelet
aggregation and stabilisation of the aggregated platelets [145,
146]. Thienopyridines (Ticlopidine, Clopidogrel,8 and Pra-
sugrel) which are nondirect, irreversible P2Y12 antagonists
are currently approved for clinical use.
Ticlopidine was the ﬁrst thienopyridine that was ap-
proved for clinical use in 1991. Ticlopidine in combination
with aspirin was superior to aspirin alone or anticoagulation
with aspirin in various clinical trials for the prevention of
recurrent ischaemic events in patients undergoing PCI [147–
150]. Ticlopidine (high rates of neutropenia) was largely re-
placed by clopidogrel (a second generation thienopyridine)
due to its better safety proﬁle [151].
Clopidogrel is the most widely used thienopyridine and
has a faster onset of action through the administration of a
loading dose [152]. The Clopidogrel versus Aspirin in Pa-
tients at Risk of Ischemic Events (CAPRIE) trial com-
pared the eﬃcacy of clopidogrel (75mg/day) and aspirin
(325mg/day) in reducing the risk of ischaemic outcomes
in patients (n = 19 185) with recent MI, recent ischaemic
stroke, or established peripheral arterial disease. The results
showed a signiﬁcantly low annual rate of ischaemic events
(ischaemic stroke, MI, or vascular death) in patients who
received clopidogrel (5.32% versus 5.83%; P = 0.043) [153].
DM subgroup had a signiﬁcantly higher beneﬁt (15.6%
versus 17.7%; P = 0.042). For every 1000 DM patients
treated with clopidogrel, 21 vascular events were prevented
[154].
Several large scale trials have shown, clear beneﬁt of
clopidogrel in addition to aspirin in preventing recurrent
ischaemic events, including stent thrombosis in the setting
of ACS (including unstable angina/NSTEMI, STEMI, PCI),
compared to aspirin alone [22, 155–159]( Table 3). Current
guidelines recommend dual antiplatelet therapy with aspirin
and clopidogrel for patients with ACS, including unstable
angina/NSTEMI, STEMI, and patients undergoing PCI [126,
127, 134]. The recommended clopidogrel dose is 300mg
loading dose (up to 600mg in PCI setting) followed by
a maintenance dose of 75mg daily. The Clopidogrel for
High Atherothrombotic Risk and Ischemic Stabilization,
Management and Avoidance (CHARISMA) trial found no
beneﬁt of dual aspirin and clopidogrel therapy in the long-
term in a wide range of non-ACS patients (n = 15603) with
risk factors for, and established atherothrombotic disease
including DM patients (n = 6555; 42% of the study pop-
ulation) [160]. Hence, dual antiplatelet therapy is not
recommended even in DM patients outside ACS/PCI setting.
In the CURRENT/OASIS-7 trial, high-dose clopidogrel
regimen (600mg loading dose, then 150mg/day for 7 days
followed by 75mg daily) signiﬁcantly reduced the rates of
cardiovascular death, MI, or stroke at 30 days (3.9% versus
4.5%; HR = 0.85; P = 0.036) as well as the risk of stent
thrombosis (0.7% versus 1.3%; HR = 0.54; P = 0.0001) in
a subgroup of patients who underwent PCI (n = 17232)
[143].ButamongDMpatients,ratesoftheprimaryoutcome
were not signiﬁcantly diﬀerent with high and standard dose
clopidogrel (4.9% versus 5.6%; HR = 0.89; 95% conﬁdence
interval [CI], 0.66 to 1.15; P = 0.434) [144].
Prasugrel is a third generation thienopyridine that was
recentlyapprovedforclinicaluseinACSpatientsundergoing
PCI. It is an orally administered, prodrug that requires
hepatic metabolism to be converted to its active metabolite
that irreversibly inhibits the P2Y12 receptor [161]. Prasugrel
has a more rapid onset of action than clopidogrel with great-
er platelet inhibition because it is converted to its active
metabolite more eﬀectively [162]. The TRial to assess Im-
provement in Therapeutic Outcomes by optimizing platelet
InhibitioN With prasugrel-Thrombolysis In Myocardial
Infarction 38 (TRITON-TIMI 38) examined the eﬃcacy and
safety of Prasugrel (60mg loading dose followed by 10mg
daily) versus clopidogrel (300mg loading dose followed by
75mg daily) in patients (n = 13608) with ACS undergoing
PCI [163]. A signiﬁcant reduction in the rates of primary
end point (consisting of cardiovascular death, nonfatal MI
or nonfatal stroke) favouring prasugrel (9.9% versus 12.1%;
HR = 0.81; P<0.001) was found. Reduction in the rates of
stent thrombosis over a follow-up period of 15 months was
also found in the prasugrel treated group, but with increased
risk of major bleeding [164]. The subgroups of patients with
DM or with STEMI had a higher beneﬁcial eﬀect. In DM
patients, the risk of primary end point was reduced sig-
niﬁcantly with prasugrel (12.2% versus 17%; HR = 0.70;
P<0.001). Prasugrel also improved the risk of stent throm-
bosis in DM subgroup (all DM patients: 2.0% versus 3.6%;
HR = 0.52; P = 0.007; insulin treated patients: 1.8% versus
5.7%; HR = 0.31; P = 0.008) [165]. Major bleeding
was higher in DM patients over all but there was no dif-
ference among DM patients treated with either prasugrel or
clopidogrel (2.6% versus 2.5%; HR = 1.06; P = 0.81).
The Optimizing antiplatelet Therapy in diabetes
MellitUS-3 (OPTIMUS-3) study showed that prasugrel
(60mg loading dose followed by 10mg/day maintenance
dose) achieved signiﬁcantly greater platelet inhibition com-
pared to double dose clopidogrel (600mg loading dose fol-
lowed by 150mg/day maintenance dose) in DM patients
with CAD. Verify Now P2Y12 assay demonstrated more
eﬀective platelet inhibition with prasugrel compared to
clopidogrel, 4 hours after the loading dose (least squares
mean, 89.3% versus 27.7%; P<0.0001). This diﬀerence in
platelet inhibition remained signiﬁcant up to 7 days after
dosing [166–168]. Higher platelet inhibition in DM patients
results in greater clinical beneﬁt as suggested by all the
above observations. The clinical eﬃcacy of prasugrel when
compared to clopidogrel in medically managed patients with
unstable angina/NSTEMI is being evaluated in the ongoing
TaRgeted platelet Inhibition to cLarify the Optimal strateGy
to medicallY manage Acute Coronary Syndrome (TRILOGY
ACS) trial.
Ticagrelor is an orally administered, direct reversible
P2Y12 inhibitor which achieves higher platelet aggregation8 Cardiology Research and Practice
Table 3: Outcomes from large-scale randomised placebo-controlled trials evaluating the eﬃcacy of dual antiplatelet therapy with aspirin
and clopidogrel versus aspirin alone in ACS/PCI patients in the overall study population and in DM patients.
Study Scenario Primary end point n (overall)
%o fe v e n t sa n d
association
measure (overall)
n (DM)
%o fe v e n t sa n d
association measure
(DM)
CURE [22] UA/NSTEMI
Cardiovascular death,
nonfatal MI, or stroke at 1
year
12 562 9.3 versus 11.4 2840 14.2 versus 16.7
RR (95% CI) 0.80 (0.72–0.90) 0.84 (0.70–1.02)
PCI-CURE
[159]
CURE patients
undergoing PCI
Cardiovascular death, MI,
or urgent TVR at 30 days 2658 4.5 versus 6.4 504 12.9 versus 16.5
RR (95% CI) 0.70 (0.50–0.97) 0.77 (0.48–1.22)
CREDO [158]E l e c t i v e P C I Death, MI, or stroke at 1
year 2116 8.5 versus 11.5 560 NR
RRR (95% CI),
% 26.9 (3.9–44.4) 11.2 (−46.8–46.2)
COMMIT [157] Acute MI (93%
STEMI)
Death, reinfarction or
stroke at discharge or 28
days
45 852 9.2 versus 10.1 NR NR
OR (95% CI) 0.91 (0.86–0.97)
CLARITY [156] STEMI with
ﬁbrinolysis
Occluded infarct-related
artery on angiography or
death or recurrent MI
before angiography
3491 15.0 versus 21.7 575 NR
OR (95% CI) 0.64 (0.53–0.76)
PCI-CLARITY
[155]
CLARITY
patients
undergoing PCI
Cardiovascular death,
r e c u r r e n tM Io rs t r o k ea t3 0
days
1863 3.6 versus 6.2 282 6.0 versus 10.1
OR (95% CI) 0.54 (0.35–0.85) 0.61 (0.24–1.53)
CURE: Clopidogrel in Unstable angina to Prevent Recurrent Events; CREDO: Clopidogrel for Reduction of Events During Observation; COMMIT:
Clopidogrel and Metoprolol in Myocardial Infarction Trial; CLARITY: Clopidogrel as Adjunctive Reperfusion Therapy; UA: Unstable Angina; TVR: Target
Vessel Revascularisation; RR: Relative Risk; RRR: Relative Risk Reduction; OR: Odds Ratio; NR: Not Reported. Adapted from [74].
inhibition compared to clopidogrel in ACS patients [169].
The PLATelet inhibition and patient Outcomes (PLATO)
trial compared ticagrelor (180mg loading dose followed by
90mg twice daily) with clopidogrel (300 to 600mg loading
dose followed by 75mg daily) in preventing cardiovascular
events in ACS patients (n = 18624). The rate of primary
end point (death resulting from MI or stroke) at 12 months
decreased signiﬁcantly in patients treated with ticagrelor
(10.2% versus 12.3%; HR = 0.84; P = 0.0001). In the
PCI subgroup the rate of CV death and stent thrombosis
reduced signiﬁcantly. Ticagrelor was not associated with
an increase in protocol deﬁned major bleeding. In DM
patients, ticagrelor reduced the rates of the primary end
point (HR = 0.88), all cause mortality (HR = 0.82) and
stent thrombosis (HR = 0.65) compared to clopidogrel.
Similar beneﬁts were seen in patients with or without in-
sulin treatment. Bleeding rates were similar (HR = 0.98) in
ticagrelor and clopidogrel treated DM patients. Side eﬀects
reportedincludeddyspnoea,ventricularpauses,andincrease
in creatinine and uric acid levels [170, 171]. Ticagrelor has
been approved for use in Europe but not yet approved for
clinical use by the FDA.
14.GPIIb/IIIaInhibitors
Three diﬀerent GP IIb/IIIa inhibitors (abciximab, tiroﬁban
and eptiﬁbatide) are currently approved for clinical use.
All these agents can be administered only intravenously,
and hence their use is limited to acute settings. A meta-
analysis of 6 large clinical trials evaluating the eﬀect of GP
IIb/IIIa inhibitors in ACS patients showed a 22% reduction
of mortality at 30 days in DM patients (n = 6458) who
received GP IIb/IIIa inhibitor compared to those who did
not (4.6% versus 6.2%; P = 0.007). Non-DM patients (n =
23072)hadnosurvivalbeneﬁt[172].Thebeneﬁtwasgreater
among the DM patients who underwent PCI during index
hospitalisation (n = 1279, 1.2% versus 4%; P = 0.002).
Unfortunately, these trials were performed using ticlopidine
or standard dose clopidogrel instead of the high loading dose
of clopidogrel. A high loading dose of clopidogrel has a more
potent antiplatelet eﬀect and is the current recommendation
for ACS patients who undergo PCI.
A recent study, the Intracoronary Stenting and Anti-
thrombotic Regimen: Is Abciximab a Superior Way to Elim-
inate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET)Cardiology Research and Practice 9
trial, compared the eﬀect of abciximab and placebo on the
1-year risk of death and MI in DM patients (n = 601)
who underwent elective PCI after pretreatment with 600mg
loading dose of clopidogrel at least 2 hours before the proce-
dure [173]. There was no beneﬁcial eﬀect from abciximab in
thisstudy,suggestingthatroutineuseofGPIIb/IIIainhibitor
in elective PCI (non-ACS setting) is not recommended.
In the Intracoronary Stenting and Antithrombotic Regi-
men: Rapid Early Action for Coronary Treatement-2 (ISAR-
REACT 2); trial, abciximab was shown to be signiﬁcantly
beneﬁcial in patients with high-risk ACS undergoing PCI
after pretreatment with 600mg of clopidogrel [174]. These
trials support the use of GP IIb/IIIa inhibitors in high-risk
ACS patients, including DM patients as recommended in the
current guidelines [126].
Ameta-regressionanalysisofrandomisedtrialsevaluated
the eﬀect of GP IIb/IIIa inhibitors in STEMI patients treated
with primary PCI. These agents showed beneﬁt in terms of
death but not re-infarction in high risk patients including
DM patients [175]. The major limitation of GP IIb/IIIa
inhibitors is the increased risk of bleeding, and it is well
known that bleeding has a signiﬁcant impact on prognosis
after an ACS, including mortality [176, 177].
15.DirectThrombin Inhibitors
Bivalirudin, a direct thrombin inhibitor, provided similar
protection from ischaemic events as GP IIb/IIIa inhibitors,
but with lower bleeding rates in the Acute Catheterisation
and Urgent Intervention Triage strategY (ACUITY) trial
[178]. In a subgroup analysis in DM patients, rates of
primaryendpoint(death,MIorunplannedischaemicrevas-
cularisation) were similar on bivalirudin monotherapy and
GP IIb/IIIa inhibitor plus heparin treatment (7.9% versus
8.9%; P = 0.39). The rate of major bleeding was signiﬁcantly
lower in the bivalirudin group (3.7% versus 7.1%; P =
0.02). This bleeding risk reduction is particularly important
because the risk of bleeding complications is increased in
diabetic patients with ACS undergoing PCI [179].
16.AntiplateletDrugResistance inDiabetes
“Resistance” means that the antiplatelet agent fails to block
its speciﬁc target (e.g., aspirin to block the COX-1 enzyme
and clopidogrel to block the P2Y12 receptor) [180]. Aspirin
resistance is associated with a higher risk of recurrent is-
chaemic events [181, 182]. COX-1-speciﬁc tests (urine
thromboxane and assays using arachidonic acid as an ago-
nist)andnon-COX-1-speciﬁctestsareavailable.Poorpatient
compliance is the main reason for aspirin resistance when
a COX-1-speciﬁc test is used [183]. DM patients respond
inadequately to aspirin when assessed by non-COX-1-
speciﬁc tests [184, 185]. In the Aspirin-Induced Platelet Ef-
fect (ASPECT) study, a subanalysis showed that aspirin
resistance was common in DM patients while on a low
dose (81mgdaily). Increasing the aspirin dose (162 and
325mgdaily)signiﬁcantlyreducedtheplateletactivity[186].
There has been no study designed to date to assess the
implications of aspirin resistance in DM patients with ACS.
Hyperglycaemia,increasedTXA2 synthesis,increasedplatelet
turnover, and TXA2 receptor (TP receptor) activation have
all been proposed to play a key role in aspirin resistance in
DM patients [187, 188].
Genetic, cellular, and clinical mechanisms contribute to
inadequate clopidogrel responsiveness [189, 190]. DM is
an important factor contributing to decreased clopidogrel
eﬀects.DM patients show lower response to clopidogrel both
in the loading phase and in the maintenance phase when
compared to non-DM patients [184, 191, 192]. DM pa-
tients who are on insulin have the highest degree of platelet
reactivity while on dual antiplatelet therapy [193]. Chronic
kidney disease in DM patients has been associated with
impaired clopidogrel response [194]. All these ﬁndings
suggest why DM is associated with higher risk of recurrent
ischaemic events in patients with ACS [22] and is a strong
predictor of stent thrombosis [195–197].
17.FutureTreatment OptionsinDiabetic
Patients withACS
Persistent high platelet activity in DM patients despite
currentrecommendedantiplatelettherapyhasraisedinterest
in identifying strategies to optimise platelet inhibition in this
high-risk population.
18. Dose Modiﬁcation of AntiplateletAgents
The OPTIMUS study showed marked improvement in
platelet inhibition when 150mg maintenance dose of clopi-
dogrel was used in DM patients with CAD [167]. In the
GaugingResponsivenesswithAVerifyNowAssay-ImpactOn
Thrombosis And Safety (GRAVITAS) trial, high clopidogrel
dose (600mg loading dose followed by 150mg daily main-
tenance dose for 6 months) was given to patients with inade-
quateresponsetostandardclopidogreldose.Atsixmonthsof
followup, the composite end point of cardiovascular death/
MI/stent thrombosis was identical in both groups, at 2.3%
(HR = 1.01; 95% CI, 0.58–1.76; P = 0.97). Stent thrombosis
occurred in 0.5% of the high-dose group and 0.7% of
the standard-dose group, a nonsigniﬁcant diﬀerence. There
was also no diﬀerence in bleeding [198]. So there is no
evidence that increase in the dose clopidogrel will improve
the outcomes in patients with T2DM.
19. Newer Agents
19.1. Picotamide. Picotamide is an inhibitor of both TXA2
synthase and TP receptor. Increased platelet turnover in DM
generates new platelets that have not been exposed to aspirin
and hence continue to generate TXA2. Therefore, TP re-
ceptors may remain activated despite COX-1 inhibition,
contributing to aspirin hyporesponsiveness. This suggests
thatTPantagonismmaypotentiallybethefutureantiplatelet
target for new pharmacological agents [199]. The Drug
evaluation in Atherosclerotic Vascular disease In Diabetics
(DAVID) trial compared picotamide with aspirin in DM10 Cardiology Research and Practice
patients with peripheral arterial disease. The 2-year overall
mortality was signiﬁcantly lower among those treated with
picotamide comparedtothose receivingaspirin (3.0%versus
5.5%; P=0.0474) [200]. Other newer agents such as ridogrel
(TXA2 synthase inhibitor and TP receptor blocker), NCX
4016 (NO-releasing aspirin derivative) and terutroban (TP
receptor inhibitor) have been compared with aspirin in
diﬀerent studies and might be of interest in the future in DM
patients [201–204].
19.2. Cangrelor. This is an intravenous, direct acting and re-
versibleP2Y12 receptorinhibitor[205].PhaseIItrialsshowed
cangrelor to be a potent antiplatelet agent achieving a greater
degree of platelet inhibition (>90%) with extremely rapid
onset and oﬀset of action [206]. However, the Cangrelor ver-
sus Standard Therapy to Achieve Optimum Management of
Platelet Inhibition (CHAMPION) study failed to show any
superiority of cangrelor over clopidogrel [207, 208].
19.3. Cilostazol. This is a phosphodiesterase III (PDE III)
inhibitor that increases intraplatelet cAMP concentration.
This drug may be considered in the maintenance phase of
therapy along with standard dual antiplatelet therapy. A
reductionintherateoftargetlesionrevascularisationandin-
stent thrombosis has been observed in patients undergoing
PCI, with this triple therapy [163, 209]. The beneﬁt is
greater in DM patients [210, 211]. The OPTIMUS-2 study
also demonstrated markedly increased inhibition of platelet
P2Y12 signalling in DM patients who received Cilostazol in
combination with dual antiplatelet therapy [168]. Cilostazol
in addition to aspirin and clopidogrel improved long-term
outcomes after PCI in patients with ACS. In this study, ACS
patients (n = 1212) were randomised to either standard
dual antiplatelet therapy or triple therapy with addition of
Cilostazol for 6 months after a successful PCI. The triple
therapy group had a signiﬁcantly lower incidence (10.3%
versus 15.1%; HR = 0.65; P = 0.011) of the primary end
point (cardiac death, nonfatal MI, stroke, or target vessel
revascularisation at 1 year after randomisation) [212]. No
signiﬁcant diﬀerences were noted in the risks for major and
minor bleeding. The use, however, is limited by the side
eﬀects that include headache, palpitations, and gastrointesti-
nal disturbances.
19.4.ThrombinReceptorAntagonists. Thrombinisanimpor-
tant link in the coagulation cascade and is a potent agonist of
platelet aggregation. Generation of thrombin is enhanced in
DM patients and hence is a potential target for treatment.
Two oral thrombin receptor antagonists are in clinical
development, vorapaxar, and atopaxar [213]. Vorapaxar had
an excellent safety proﬁle when used concomitantly with
aspirin and clopidogrel in a large phase II study [214].
Two large-scale phase III trials were conducted to evaluate
the safety and eﬃcacy of vorapaxar, the Trial to Assess the
Eﬀects of vorapaxar in Preventing Heart Attack and Stroke
in Patients with Atherosclerosis (TRA-2P) in atherosclerosis
patients and the Trial to Assess the Eﬀects of vorapaxar
in Preventing Heart Attack and Stroke in patients with
ACS (TRACER) in ACS patients. An increase in intracranial
haemorrhage in patients with stroke was observed in these
trials. Hence TRACER trial was discontinued earlier this year
and the accumulated data are yet to be presented. In TRA-2P
trial, the study drug is being given only to patients with MI
and peripheral vascular disease. The study drug has been
withdrawnornotbeinggiventothosewithahistoryofstroke
or who have suﬀered a stroke during the course of the trial.
Atopaxar has also shown promising results from phase II
trial [215]. Further studies with these agents will provide an
insight in to their use in the future.
20.Newer Oral Anticoagulants
In DM patients, the enhanced atherothrombotic risk is not
only due to platelet reactivity but also due to dysregulation
of coagulation processes. These include increased plasma
coagulation factors (Factor VII and thrombin), TF, PAI-1,
and decreased endogenous anticoagulants (Protein C and
thrombomodulin). Several new oral anticoagulants, includ-
ing antifactor IIa (Dabigatran) and antifactor Xa (Rivarox-
aban, apixaban) agents, are currently being tested for long-
term use in ACS patients as an adjunct to dual antiplatelet
therapy, in which DM patients represent a cohort of special
interest [216, 217].
21. Management of Endothelial
DysfunctioninDM
In spite of the predominant role played by oxidative stress in
DM and atherosclerosis, antioxidant therapy had no beneﬁt
in large randomised control trials [218–220]. ACEIs and
angiotensin receptor blockers (ARB’s) decrease superoxide
production by NADPH oxidase and hence are beneﬁcial in
DM patients. Statin therapy improves endothelial function,
reduces free radical production, and inhibits proinﬂam-
matory mechanisms in DM patients. Practical methods to
monitor endothelial function in DM patients and to help in
optimising therapy accordingly might be useful in the future.
22. Further ClinicalStudiesinDM
Anti-inﬂammatory drugs, PKCβ inhibitors, and NFκB in-
hibitors appear to hold great promise and clinical studies
usingtheseagentsareinprogress.Preliminaryworkondrugs
that have favourable eﬀects on mitochondrial function (mi-
tochondrial superoxide production, biogenesis, dynamics,
and autophagy) has been promising.
23. Conclusion
DM patients have increased atherothrombotic risk and
recurrent ischaemic events following acute coronary syn-
drome and PCI despite being on currently recommended
dual antiplatelet therapy, when compared to the nondiabetic
population. This may partly be due to abnormal endothelial
function, abnormal platelet haemostasis resulting in platelet
hyperactivity,anddysregulationinthecoagulationprocesses.Cardiology Research and Practice 11
GPIIb/IIIainhibitorsandbivalirudinhaveshowntoimprove
acute outcomes in DM patients with ACS. Current dual
antiplatelet therapy has proved successful in improving the
outcomes in DM patients with ACS and remains the main
stay of treatment for long-term secondary prevention and
reduction of stent thrombosis. However, in the presence of
DM,plateletactivityandrecurrentthromboticeventsremain
signiﬁcantly high in spite of the currently recommended
antiplatelet and antithrombotic therapies. Therefore, more
potentantithrombotictherapiesarewarrantedforthisgroup
of high risk patients. Clinical studies with novel therapies
may provide important treatment alternatives in the future
to tackle this thrombotic burden.
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